Physician
Meriter Hospital, INC.
Meriter Hospital, INC. was paid $25.44M by Medicaid between Jan 2018 and Dec 2024, across 335 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 9.8% of everything it billed.
33Billing provider infoMERITER HOSPITAL, INC.
MADISON, WI 53715
MADISON, WI 53715
33aNPI1114920048assigned 05/24/2005
33bProvider typeGeneral Practice Physician
28Total paid$25.44M
24GClaims1,097,351
24DCodes billed335
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Practice Physician providers in Wisconsin
Rank by total paid#1 of 20
Median peer was paid$18K
This provider vs. median1,443×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 122,450 | $2.86M | |
| 2019 | 141,137 | $3.25M | |
| 2020 | 131,362 | $2.91M | |
| 2021 | 173,153 | $3.26M | |
| 2022 | 181,711 | $3.52M | |
| 2023 | 193,237 | $5.11M | |
| 2024incomplete | 154,301 | $4.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 9.8% | 22,842 | 16,106 | $2.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.6% | 40,245 | 34,783 | $2.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.8% | 40,986 | 34,743 | $2.24M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.8% | 21,372 | 18,086 | $964K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.3% | 2,718 | 2,260 | $841K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 15,784 | 8,811 | $770K |
| J2350 | Injection, ocrelizumab, 1 mg | 2.5% | 173 | 152 | $638K |
| 80053 | Comprehensive metabolic panel | 2.1% | 38,638 | 30,769 | $546K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 2.1% | 12,649 | 2,271 | $525K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.0% | 9,178 | 6,830 | $516K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 6,880 | 5,196 | $514K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 2.0% | 1,935 | 1,629 | $501K |
323 more codes
| 59025 | Fetal non-stress test | 2.0% | 9,611 | $498K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.9% | 11,090 | $473K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.7% | 9,607 | $432K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 1.7% | 2,326 | $430K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 6,826 | $428K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 5,959 | $400K |
| 96040 | 1.5% | 4,927 | $376K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 9,623 | $374K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.5% | 5,665 | $371K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 5,764 | $353K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 7,689 | $329K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 5,344 | $305K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.2% | 10,581 | $303K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.0% | 4,073 | $264K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,296 | $237K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 1,170 | $232K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,083 | $206K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,737 | $204K |
| 90837 | Psychotherapy session, about an hour | <1% | 7,974 | $201K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,038 | $199K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,626 | $175K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,078 | $167K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,559 | $164K |
| 96415 | <1% | 2,219 | $158K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,611 | $155K |
| 76801 | <1% | 3,732 | $155K | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 116 | $151K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,846 | $149K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,086 | $147K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,519 | $140K |
| 87210 | <1% | 10,017 | $137K | |
| 80305 | <1% | 10,444 | $134K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,151 | $128K |
| 86850 | <1% | 5,703 | $128K | |
| 82947 | <1% | 12,086 | $125K | |
| G0378 | Hospital observation service, per hour | <1% | 6,432 | $122K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,214 | $112K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,364 | $110K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 689 | $109K |
| 84484 | <1% | 15,081 | $108K | |
| 36902 | <1% | 341 | $107K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,457 | $100K |
| 82962 | <1% | 11,538 | $99K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,308 | $96K |
| 81003 | <1% | 28,079 | $87K | |
| 87631 | <1% | 999 | $85K | |
| 84702 | <1% | 4,821 | $75K | |
| 85027 | <1% | 12,999 | $72K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,219 | $71K |
| 93976 | <1% | 1,893 | $65K | |
| 82077 | <1% | 7,783 | $63K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 533 | $60K |
| 76830 | Ultrasound, transvaginal | <1% | 2,514 | $60K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,549 | $59K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 354 | $56K |
| 87081 | <1% | 2,876 | $53K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,344 | $53K |
| 83880 | <1% | 2,841 | $50K | |
| 83690 | <1% | 11,797 | $48K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,612 | $45K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 716 | $44K |
| 80143 | <1% | 3,751 | $44K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 26,295 | $43K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,635 | $42K |
| 76857 | <1% | 2,565 | $41K | |
| 84703 | <1% | 7,360 | $41K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,061 | $40K |
| 80329 | <1% | 1,187 | $39K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 167 | $38K |
| H2012 | Behavioral health day treatment, per hour | <1% | 318 | $37K |
| 87150 | <1% | 1,102 | $37K | |
| 82570 | <1% | 3,765 | $37K | |
| 81025 | <1% | 5,522 | $37K | |
| 93971 | <1% | 1,705 | $36K | |
| 64400 | <1% | 285 | $35K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 452 | $34K |
| 82105 | <1% | 408 | $33K | |
| 80179 | <1% | 3,646 | $31K | |
| 86900 | <1% | 6,039 | $30K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,353 | $28K |
| 87506 | <1% | 231 | $27K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 856 | $27K |
| 82565 | <1% | 1,867 | $26K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 823 | $25K |
| 0240U | <1% | 846 | $25K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,185 | $24K |
| 83735 | <1% | 6,622 | $24K | |
| 83605 | <1% | 4,005 | $23K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,639 | $22K |
| 87070 | <1% | 1,134 | $21K | |
| 82803 | <1% | 1,566 | $21K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 151 | $19K |
| 85379 | <1% | 3,480 | $19K | |
| 87040 | <1% | 3,283 | $18K | |
| 12001 | <1% | 277 | $17K | |
| 84145 | <1% | 1,382 | $17K | |
| 70486 | <1% | 629 | $17K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,144 | $16K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 543 | $15K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 695 | $15K |
| 76813 | <1% | 820 | $15K | |
| 87186 | <1% | 2,256 | $14K | |
| 80076 | <1% | 2,621 | $13K | |
| 93325 | <1% | 516 | $13K | |
| 76820 | <1% | 3,520 | $13K | |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 15 | $13K |
| 85610 | <1% | 5,687 | $12K | |
| 93296 | <1% | 772 | $12K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,855 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,586 | $11K |
| 86901 | <1% | 6,035 | $11K | |
| 81001 | <1% | 1,198 | $10K | |
| 99442 | <1% | 778 | $9K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 163 | $9K |
| 86140 | <1% | 3,270 | $9K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 394 | $9K |
| 84439 | <1% | 1,100 | $9K | |
| 90715 | <1% | 1,699 | $9K | |
| 84156 | <1% | 3,069 | $9K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 210 | $8K |
| 84460 | <1% | 2,598 | $8K | |
| 99253 | <1% | 155 | $8K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 276 | $7K |
| 84100 | <1% | 2,769 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,296 | $7K |
| 84450 | <1% | 1,248 | $7K | |
| 36581 | <1% | 18 | $7K | |
| 58661 | <1% | 22 | $7K | |
| 86780 | <1% | 736 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 118 | $7K |
| 12011 | <1% | 107 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 392 | $6K |
| 82550 | <1% | 1,502 | $6K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 16 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,932 | $6K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 51 | $6K |
| 84132 | <1% | 1,397 | $6K | |
| 85730 | <1% | 1,760 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,810 | $5K |
| 94660 | <1% | 443 | $5K | |
| 87632 | <1% | 39 | $5K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,105 | $5K |
| 76825 | <1% | 163 | $5K | |
| 87653 | <1% | 93 | $4K | |
| 87088 | <1% | 833 | $4K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 489 | $4K |
| 82728 | <1% | 366 | $4K | |
| 99443 | <1% | 327 | $4K | |
| 76821 | <1% | 1,040 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 19 | $4K |
| 82010 | <1% | 781 | $3K | |
| 90686 | <1% | 1,047 | $3K | |
| 12002 | <1% | 52 | $3K | |
| 87077 | <1% | 451 | $3K | |
| 86803 | <1% | 508 | $3K | |
| 80061 | Lipid panel | <1% | 250 | $3K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 19 | $3K |
| 84112 | <1% | 28 | $3K | |
| 87147 | <1% | 655 | $2K | |
| 58558 | <1% | 16 | $2K | |
| 87205 | <1% | 930 | $2K | |
| 87184 | <1% | 534 | $2K | |
| 29125 | <1% | 31 | $2K | |
| 76000 | <1% | 616 | $2K | |
| 87641 | <1% | 127 | $2K | |
| 87340 | <1% | 412 | $2K | |
| 85651 | <1% | 1,139 | $2K | |
| 96367 | <1% | 13 | $2K | |
| 84163 | <1% | 198 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,334 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 120 | $2K |
| 70498 | <1% | 16 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 105 | $1K |
| 73562 | <1% | 1,410 | $1K | |
| 85652 | <1% | 843 | $1K | |
| 76827 | <1% | 161 | $1K | |
| 76942 | <1% | 234 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 41 | $1K |
| 10061 | <1% | 27 | $1K | |
| 96127 | <1% | 570 | $1K | |
| 87493 | <1% | 72 | $1K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 29 | $1K |
| 73610 | <1% | 658 | $990.59 | |
| 99254 | <1% | 16 | $987.72 | |
| 70496 | <1% | 13 | $987.03 | |
| 86870 | <1% | 20 | $936.36 | |
| 91322 | <1% | 162 | $934.16 | |
| 96376 | <1% | 6,292 | $891.36 | |
| 93017 | <1% | 51 | $851.24 | |
| 80051 | <1% | 42 | $847.94 | |
| 36901 | <1% | 12 | $829.02 | |
| 73630 | <1% | 1,711 | $715.08 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $696.12 |
| 74018 | <1% | 915 | $659.41 | |
| 99152 | <1% | 1,532 | $658.74 | |
| 73130 | <1% | 1,396 | $636.06 | |
| 73030 | <1% | 870 | $626.23 | |
| 94729 | <1% | 81 | $577.25 | |
| 84550 | <1% | 84 | $566.42 | |
| 83021 | <1% | 44 | $523.60 | |
| 86787 | <1% | 108 | $522.51 | |
| Q3014 | Telehealth originating site facility fee | <1% | 338 | $518.96 |
| 80050 | General health panel | <1% | 1,187 | $466.14 |
| 90674 | <1% | 119 | $448.84 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,355 | $438.47 |
| 82950 | <1% | 30 | $417.66 | |
| 97162 | <1% | 148 | $411.40 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 14 | $388.54 |
| 83540 | <1% | 108 | $380.46 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 17 | $373.01 |
| 90677 | <1% | 37 | $367.92 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,101 | $367.53 |
| 85018 | <1% | 363 | $351.87 | |
| 76770 | <1% | 13 | $350.30 | |
| 72100 | <1% | 401 | $323.66 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,763 | $305.38 |
| 73110 | <1% | 450 | $304.43 | |
| 85384 | <1% | 46 | $303.66 | |
| 83550 | <1% | 63 | $301.10 | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,237 | $287.45 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,926 | $281.00 |
| 0042T | <1% | 12 | $269.72 | |
| 90480 | <1% | 164 | $239.47 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,768 | $224.47 |
| 90656 | <1% | 68 | $218.42 | |
| 82977 | <1% | 49 | $209.67 | |
| 86762 | <1% | 17 | $178.44 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,934 | $167.14 |
| 82607 | <1% | 18 | $155.80 | |
| 73502 | <1% | 141 | $154.95 | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 59 | $137.62 |
| 80164 | <1% | 15 | $129.59 | |
| 83020 | <1% | 27 | $122.17 | |
| 85007 | <1% | 234 | $105.01 | |
| 88307 | <1% | 78 | $104.47 | |
| 86308 | <1% | 28 | $101.65 | |
| 80178 | <1% | 29 | $95.62 | |
| 94010 | <1% | 29 | $91.45 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 12,637 | $89.46 |
| 82247 | <1% | 45 | $89.04 | |
| 87075 | <1% | 15 | $88.11 | |
| 90678 | <1% | 19 | $84.78 | |
| 81015 | <1% | 484 | $74.56 | |
| 90694 | <1% | 112 | $68.96 | |
| 80320 | <1% | 1,355 | $66.24 | |
| 97166 | <1% | 12 | $62.66 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,676 | $45.54 |
| 88304 | <1% | 437 | $33.30 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,602 | $32.98 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 51 | $23.39 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,748 | $21.13 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,482 | $19.17 |
| 88342 | <1% | 397 | $19.06 | |
| 83615 | <1% | 18 | $18.72 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,817 | $17.58 |
| 80348 | <1% | 17 | $15.38 | |
| C1769 | Guide wire | <1% | 1,258 | $14.14 |
| 85049 | <1% | 12 | $12.42 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,613 | $12.40 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,693 | $11.61 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,587 | $10.98 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,431 | $10.71 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,114 | $10.42 |
| 73590 | <1% | 71 | $10.18 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 518 | $8.75 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,491 | $8.51 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 130 | $7.59 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 187 | $7.37 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 950 | $6.38 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 278 | $5.99 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,519 | $5.40 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 39 | $4.75 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 866 | $4.44 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,422 | $3.39 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,410 | $2.54 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 110 | $2.29 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 739 | $2.08 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 361 | $1.82 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 131 | $1.78 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,512 | $1.76 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 76 | $1.67 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 329 | $1.55 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,875 | $1.42 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,128 | $1.10 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,494 | $0.75 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 311 | $0.73 |
| A9270 | Non-covered item or service | <1% | 11,005 | $0.33 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 24 | $0.18 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 1,251 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,006 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 695 | $0.00 |
| C1888 | Catheter, ablation, non-cardiac, endovascular (implantable) | 0% | 794 | $0.00 |
| 74019 | 0% | 26 | $0.00 | |
| 36591 | 0% | 52 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 980 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 63 | $0.00 |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | 0% | 50 | $0.00 |
| 51798 | 0% | 74 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 79 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 73 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 179 | $0.00 |
| 77001 | 0% | 25 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 32 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 47 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 29 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 458 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 3,124 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 66 | $0.00 |
| J2359 | Injection, olanzapine, 0.5 mg | 0% | 565 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 909 | $0.00 |
| 0124A | 0% | 126 | $0.00 | |
| 0054A | 0% | 67 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 276 | $0.00 |
| T1013 | Sign language or oral interpretive services, per 15 minutes | 0% | 530 | $0.00 |
| 0003A | 0% | 16 | $0.00 | |
| 88302 | 0% | 18 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 192 | $0.00 |
| 73140 | 0% | 44 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 73 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| 90653 | 0% | 15 | $0.00 | |
| 73080 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERDMAN, BETH (CFO)
| Provider | Location | Paid |
|---|---|---|
| Meriter Health Enterprises INC. | Madison, WI | $1.05M |
| Meriter Hospital, INC. | Madison, WI | $803K |
| Meriter Hospital, INC. | Madison, WI | $289K |
| Meriter Hospital, INC. | Madison, WI | $513.54 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.